Potential Benefits of Pitavastatin in HIV Patients from REPRIEVE Trial Sub-Study

This chapter delves into a sub-study of the REPRIEVE trial focusing on Pitavastatin's effects on cardiovascular events and coronary plaques in people with HIV. It discusses significant risk reductions, changes in plaque characteristics, and the association with inflammatory markers observed in the study. The speakers explore the mechanistic observations to understand the lower incidence of adverse atherosclerotic events in this population.